Ibrutinib has demonstrated marked efficacy in chronic lymphocytic leukemia (CLL). Jacqueline Barrientos, MD, Northwell Health, New York, NY, outlines the toxicity profile of ibrutinib and discusses the extended follow-up results of the E1912 trial (NCT02048813). Among the 95 patients who discontinued ibrutinub, 51% was due to adverse events and toxicities. Dr Barrientos reveals that adverse events should be identified early to avoid greater complications. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.